BA
DXCM icon

Bridgewater Associates’s DexCom DXCM Stock Holding History

Bridgewater Associates’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27M Buy
400,929
+261,242
+187% +$17.4M 0.11% 153
2026
Q1 		$8.77M Sell
139,687
-9,577
-6% -$667K 0.04% 291
2025
Q4 		$9.91M Buy
149,264
+28,769
+24% +$1.86M 0.04% 359
2025
Q3 		$8.11M Sell
120,495
-133,316
-53% -$10.6M 0.03% 367
2025
Q2 		$22.2M Buy
253,811
+182,515
+256% +$14.3M 0.09% 169
2025
Q1 		$4.87M Sell
71,296
-26,642
-27% -$2.17M 0.02% 361
2024
Q4 		$7.62M Sell
97,938
-221,691
-69% -$16.4M 0.03% 289
2024
Q3 		$21.4M Sell
319,629
-27,695
-8% -$2.27M 0.12% 148
2024
Q2 		$39.4M Sell
347,324
-23,540
-6% -$2.98M 0.21% 81
2024
Q1 		$51.4M Sell
370,864
-62,291
-14% -$7.83M 0.26% 72
2023
Q4 		$53.8M Sell
433,155
-168,208
-28% -$17.2M 0.3% 66
2023
Q3 		$56.1M Buy
601,363
+183,141
+44% +$20.6M 0.34% 57
2023
Q2 		$53.7M Sell
418,222
-37,149
-8% -$4.49M 0.33% 64
2023
Q1 		$52.9M Buy
455,371
+23,847
+6% +$2.67M 0.32% 63
2022
Q4 		$48.9M Sell
431,524
-191,759
-31% -$21.1M 0.27% 79
2022
Q3 		$50.2M Sell
623,283
-9,771
-2% -$828K 0.25% 79
2022
Q2 		$47.2M Buy
633,054
+52,090
+9% +$4.75M 0.2% 104
2022
Q1 		$74.3M Buy
580,964
+154,828
+36% +$16.9M 0.3% 60
2021
Q4 		$57.2M Buy
426,136
+49,124
+13% +$7.06M 0.33% 51
2021
Q3 		$51.5M Sell
377,012
-44,636
-11% -$5.63M 0.28% 69
2021
Q2 		$45M Buy
421,648
+275,520
+189% +$26.5M 0.29% 67
2021
Q1 		$13.1M Buy
146,128
+16,032
+12% +$1.5M 0.12% 139
2020
Q4 		$12M Buy
130,096
+60,420
+87% +$5.39M 0.1% 107
2020
Q3 		$7.18M Buy
+69,676
New +$7.28M 0.09% 105

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bridgewater Associates's DXCM Position: Q2 2026 in Review

Bridgewater Associates increased its DexCom (DXCM) stake by 187% in Q2 2026, buying an estimated $17.4M and bringing the position to 400,929 shares worth $27M. The position accounts for 0.11% of the portfolio, ranked #153.

Bridgewater Associates first reported a position in DXCM in Q3 2020 and has held it in 24 quarters since. The position peaked at $74.3M in Q1 2022. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Bridgewater Associates held 400,929 shares of DexCom worth $27M as of Q2 2026.
  • Bridgewater Associates bought 261,242 DexCom shares in Q2 2026, an estimated $17.4M.
  • DexCom made up 0.11% of Bridgewater Associates's portfolio in Q2 2026, its #153 holding.
  • Bridgewater Associates first reported a position in DexCom in Q3 2020 and has held it in 24 quarters since.
  • Bridgewater Associates's DexCom position peaked at $74.3M in Q1 2022.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Bridgewater Associates's 13F filing for Q2 2026, filed 14 Aug 2026.